Literature DB >> 18685848

Possible involvement of regulatory T cells in tumor onset and progression in primary breast cancer.

Masahiro Ohara1, Yoshiyuki Yamaguchi, Kazuo Matsuura, Shigeru Murakami, Koji Arihiro, Morihito Okada.   

Abstract

BACKGROUND: The FOXP3 mRNA expression and the other regulatory T cell-related molecules were investigated and compared with clinicopathological parameters in human primary breast cancer.
METHOD: This study included 136 breast cancer patients operated in our department from 2003 to 2006. Total RNA was extracted from frozen normal breast and breast cancer tissues, and the expression of FOXP3, IL-10, TGFbeta1 and CCL22 mRNA was evaluated using quantitative real-time RT-PCR. RESULT: FOXP3, IL-10, TGFbeta1 and CCL22 mRNA expressions were significantly higher in cancer tissue than in normal tissue, not only at pT1, 2, and 3 stages but also at the DCIS stage. There were positive correlations between FOXP3 and IL-10, FOXP3 and TGFbeta1, as well as FOXP3 and CCL22 mRNA expressions, respectively. FOXP3 and IL-10 mRNA expressions were significantly upregulated in PgR-negative or HER2-positive tumors.
CONCLUSION: These results suggest that regulatory T cells are involved in tumor onset and progression in human primary breast cancer, possibly contributing to poor prognosis of patients with breast cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18685848     DOI: 10.1007/s00262-008-0570-x

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  39 in total

1.  FOXP3 expression and nodal metastasis of breast cancer.

Authors:  Yesim Gökmen-Polar; Mangesh A Thorat; Payal Sojitra; Rashmil Saxena; Sunil Badve
Journal:  Cell Oncol (Dordr)       Date:  2013-08-31       Impact factor: 6.730

2.  IL-27 confers a protumorigenic activity of regulatory T cells via CD39.

Authors:  Young-Jun Park; Heeju Ryu; Garam Choi; Byung-Seok Kim; Eun Sook Hwang; Hun Sik Kim; Yeonseok Chung
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-04       Impact factor: 11.205

Review 3.  Mammary gland involution as an immunotherapeutic target for postpartum breast cancer.

Authors:  Jaime Fornetti; Holly A Martinson; Courtney B Betts; Traci R Lyons; Sonali Jindal; Qiuchen Guo; Lisa M Coussens; Virginia F Borges; Pepper Schedin
Journal:  J Mammary Gland Biol Neoplasia       Date:  2014-06-22       Impact factor: 2.673

Review 4.  Harnessing the immune system for the treatment of breast cancer.

Authors:  Xinguo Jiang
Journal:  J Zhejiang Univ Sci B       Date:  2014-01       Impact factor: 3.066

Review 5.  The immune system and inflammation in breast cancer.

Authors:  Xinguo Jiang; David J Shapiro
Journal:  Mol Cell Endocrinol       Date:  2013-06-19       Impact factor: 4.102

6.  Increased CTLA-4 and FOXP3 transcripts in peripheral blood mononuclear cells of patients with breast cancer.

Authors:  Mansooreh Jaberipour; Mojtaba Habibagahi; Ahmad Hosseini; Saadat Rezai Habibabad; Abdolrasoul Talei; Abbas Ghaderi
Journal:  Pathol Oncol Res       Date:  2010-03-21       Impact factor: 3.201

7.  Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling.

Authors:  Wei Tan; Weizhou Zhang; Amy Strasner; Sergei Grivennikov; Jin Q Cheng; Robert M Hoffman; Michael Karin
Journal:  Nature       Date:  2011-02-16       Impact factor: 49.962

8.  Differential heat shock protein localization in chronic lymphocytic leukemia.

Authors:  Nina C Dempsey; Francesca Leoni; H Elyse Ireland; Christine Hoyle; John H H Williams
Journal:  J Leukoc Biol       Date:  2009-12-10       Impact factor: 4.962

9.  The role of regulatory T cells in cancer.

Authors:  Tai-You Ha
Journal:  Immune Netw       Date:  2009-12-31       Impact factor: 6.303

Review 10.  FoxP3 Expression in Macrophages, Cancer, and B Cells-Is It Real?

Authors:  Zahava Vadasz; Elias Toubi
Journal:  Clin Rev Allergy Immunol       Date:  2017-06       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.